Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioFactura, Inc.
BioFactura, which is already using its ‘StableFast’ technology platform to develop its biosimilar ustekinumab candidate, has allied with fellow US-based biotech Rani Therapeutics to see if the biologic can be formulated into Rani’s proprietary ‘robotic’ pill.
- Other Names / Subsidiaries
- Burrell International Group, LLC